drugset / Trial / NCT06578533
Keeping RAASi Treatment With Optimal Potassium Control
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase III, multicenter, randomized, open-label, parallel-group, non-inferiority, phase III clinical trial comparing CSZ (Lokelma) vs. iSRAA discontinuation/reduction and/or ARM (standard treatment).
Timeline
- Start
- 2022-09-30
- Primary completion
- 2025-07-30
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Zirconium Cyclosilicate | Other / unclassified | 10 g | Oral |